Skip to content
No results
  • Home
  • News
  • Press Releases
  • Business
  • Technology
  • Research
  • Regulatory
  • Events and Conferences
  • About Us
  • Contact Us
  • About Us
  • Contact Us
The Pharma Data
  • News
  • Press Releases
  • Business
  • Technology
  • Research
  • Regulatory
  • Events and Conferences
The Pharma Data
Endometrial Cancer,Faeth
  • News

Faeth Therapeutics & GOG-F Launch Phase 2 Trial for Sapanisertib-Serabelisib in Endometrial Cancer

  • The Pharma Data
  • March 13, 2025

Faeth Therapeutics & GOG-F Launch Phase 2 Trial for Sapanisertib-Serabelisib in Endometrial Cancer Faeth Therapeutics (Faeth), a clinical-stage biotechnology company dedicated to pioneering novel metabolism-based therapeutic strategies, and The GOG…

Read MoreFaeth Therapeutics & GOG-F Launch Phase 2 Trial for Sapanisertib-Serabelisib in Endometrial Cancer
Financial Results
  • Press Releases

Biote Announces Q4 and Full-Year 2024 Financial Results

  • The Pharma Data
  • March 13, 2025

Biote Announces Fourth Quarter and Full-Year 2024 Financial Results Biote, a leading provider of personalized hormone optimization and therapeutic wellness solutions, has released its financial results for the fourth quarter…

Read MoreBiote Announces Q4 and Full-Year 2024 Financial Results
Antiviral
  • Research

SCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 Post-Exposure

  • The Pharma Data
  • March 13, 2025

SCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 Post-Exposure Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) presented late-breaking scientific…

Read MoreSCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 Post-Exposure
Merck ,HIV
  • Press Releases

Merck’s Phase 3 Trials Show DOR/ISL Maintains HIV-1 Suppression at 48 Weeks

  • The Pharma Data
  • March 13, 2025

Merck’s Phase 3 Trials Show DOR/ISL Maintains HIV-1 Suppression at 48 Weeks Merck, known as MSD outside of the United States and Canada, has announced promising results from two pivotal…

Read MoreMerck’s Phase 3 Trials Show DOR/ISL Maintains HIV-1 Suppression at 48 Weeks
HIV Treatment
  • Press Releases

Gilead Unveils New HIV Treatment Data at CROI 2025

  • The Pharma Data
  • March 13, 2025

Gilead Unveils New HIV Treatment Data at CROI 2025 Gilead Sciences, Inc. has unveiled a significant array of late-breaking data and multiple oral presentations from its groundbreaking HIV treatment portfolio…

Read MoreGilead Unveils New HIV Treatment Data at CROI 2025
City of Hopes
  • NewsResearch

City of Hope’s Phase 1 Trial Featured at SSO Annual Meeting

  • The Pharma Data
  • March 13, 2025

City of Hope’s Phase 1 Trial Featured at SSO Annual Meeting City of Hope’s groundbreaking Phase 1 clinical trial has demonstrated promising results for patients suffering from colorectal and appendiceal…

Read MoreCity of Hope’s Phase 1 Trial Featured at SSO Annual Meeting
Drug
  • News

LGM Pharma Invests $6M to Expand U.S. Drug Manufacturing

  • The Pharma Data
  • March 13, 2025

LGM Pharma Invests $6 Million to Expand U.S. Drug Manufacturing Capabilities LGM Pharma, a leading provider of tailored active pharmaceutical ingredient (API) and contract development and manufacturing organization (CDMO) services,…

Read MoreLGM Pharma Invests $6M to Expand U.S. Drug Manufacturing
Shift Bioscience
  • Regulatory

Shift Bioscience Strengthens Team for Rejuvenation Therapeutics

  • The Pharma Data
  • March 13, 2025

Shift Bioscience Strengthens Leadership Team to Accelerate Rejuvenation Therapeutics Development Shift Bioscience, a pioneering biotechnology company utilizing an AI-powered virtual cell platform to combat age-related diseases, has announced the strategic…

Read MoreShift Bioscience Strengthens Team for Rejuvenation Therapeutics
Biopharma Solutions
  • Press Releases

PharmaCord & Mercalis Merge to Advance Biopharma Solutions

  • The Pharma Data
  • March 13, 2025

PharmaCord & Mercalis Merge to Advance Biopharma Solutions PharmaCord LLC (“PharmaCord”), a leading provider of patient services for the biopharmaceutical industry, and Mercalis, an integrated life sciences commercialization partner, have…

Read MorePharmaCord & Mercalis Merge to Advance Biopharma Solutions
InTandem,Clinilabs
  • Press Releases

InTandem Capital Invests in Clinilabs

  • The Pharma Data
  • March 13, 2025

InTandem Capital Invests in Clinilabs InTandem Capital Partners (“InTandem Capital” or the “Firm”), a private equity firm specializing in healthcare services, has officially announced its strategic partnership with Clinilabs (the…

Read MoreInTandem Capital Invests in Clinilabs
Generative AI Reshapes the Disparate Health Technology Assessment Landscape
  • Press Releases

Generative AI Reshapes the Disparate Health Technology Assessment Landscape

  • The Pharma Data
  • March 12, 2025

Generative AI Revolutionizes Health Technology Assessment Landscape: Trinity Life Sciences Enhances HTA Vision Trinity Life Sciences, a leading provider of strategy, insights, and analytics for the life sciences industry, has…

Read MoreGenerative AI Reshapes the Disparate Health Technology Assessment Landscape
Seismic Therapeutic Starts Phase 1 Trial of S-1117 for Antibody-Mediated Diseases
  • Research

Seismic Therapeutic Starts Phase 1 Trial of S-1117 for Antibody-Mediated Diseases

  • The Pharma Data
  • March 12, 2025

Seismic Therapeutic Starts Phase 1 Trial of S-1117 for Antibody-Mediated Diseases Seismic Therapeutic, Inc., a machine learning-driven immunology company, has announced a significant milestone in its journey toward developing transformative…

Read MoreSeismic Therapeutic Starts Phase 1 Trial of S-1117 for Antibody-Mediated Diseases
PrevNext

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • EmeraNova™ Strengthens Innovation Leadership with Launch of New Accelerator ProgramNovember 5, 2026
  • Global Healthy Living Foundation Highlights Advances in Myositis and Polymyalgia Rheumatica Research at ACR Convergence 2026November 5, 2026
  • Polaris Rx Chosen by Bristol Myers Squibb to Distribute ZENBEXUS™, the First FDA-Approved CELMoD Treatment for Multiple MyelomaNovember 5, 2026
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.